Showing results (151-160 of 188) with videos related to
Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2004
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B studySherif S Farag, Amy S Ruppert, Krzysztof Mrózek, et al.Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.Clinical Lymphoma, Myeloma & Leukemia|August 2, 2021
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic LeukemiaMatthew C Cheung, Nicole Mittmann, Carolyn Owen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2025
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2005
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B studyGuido Marcucci, Claudia D Baldus, Amy S Ruppert, et al.Plos One|October 17, 2013
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseErin Hertlein, Kyle A Beckwith, Gerard Lozanski, et al.Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.Blood Advances|January 4, 2018
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinibTracy E Wiczer, Lauren B Levine, Jessica Brumbaugh, et al.JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.Pageof 19